Sera Prognostics (SERA) AI Stock Analysis

• Market Cap: $127.89M
• Dividend Yield: N/A
• Average Volume (3M): 52.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 0.93%
• EPS Growth: 13.99%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.16
• Shares Outstanding: 37,094,110
• 10 Day Avg. Volume: 44,362
• 30 Day Avg. Volume: 52,924
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 889.86
• Enterprise Value/Gross Profit: -425.24
• Enterprise Value/Ebitda: -3.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: $3.00 ▼(-10.98% Downside)

Sera Prognostics' overall stock score is primarily impacted by its poor financial performance, characterized by significant losses and negative cash flows. While there are positive strategic initiatives and short-term technical indicators, these are overshadowed by the company's ongoing financial challenges and negative valuation metrics.

Positive Factors

Medicaid Program Engagement

Engagement with Medicaid programs could enhance revenue stability and expand market reach, providing a durable foundation for growth.

European Market Expansion

Expanding into Europe diversifies revenue streams and captures new market opportunities, strengthening long-term growth prospects.

Strong Cash Position

A strong cash position provides financial stability and supports strategic initiatives, reducing reliance on external funding.

Negative Factors

Decline in Net Revenue

Declining revenue indicates challenges in market penetration and sales growth, impacting long-term financial health.

Net Loss

Continued net losses highlight operational inefficiencies and the need for improved cost management to achieve profitability.

Negative Cash Flow

Negative cash flows indicate financial strain, limiting the company's ability to invest in growth and sustain operations long-term.

Sera Prognostics Business Overview & Revenue Model

Company Description

Sera Prognostics, Inc. is a biotechnology company specializing in maternal-fetal health diagnostics. The company focuses on the development and commercialization of innovative blood tests designed to predict the risk of adverse pregnancy outcomes, such as preterm birth and other complications. Its flagship product, the SeraTest, leverages advanced proteomics to provide healthcare providers with actionable insights for better management of pregnancies, ultimately aiming to improve maternal and infant health outcomes.

How the Company Makes Money

Sera Prognostics generates revenue primarily through the sale of its diagnostic tests, including the SeraTest, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where it charges for each test performed. Additionally, Sera may engage in partnerships with healthcare organizations and pharmaceutical companies for research collaborations and the development of new tests, which can provide additional revenue streams. Insurance reimbursements also play a significant role in the company's revenue, as many diagnostic tests are covered by health insurance plans, facilitating broader adoption of their services. Furthermore, ongoing investments in R&D to expand their product offerings can lead to new revenue opportunities in the future.

Sera Prognostics Financial Statement Overview

Summary

Sera Prognostics is facing significant financial challenges, with persistent losses and negative cash flows. The income statement reflects declining revenues and profitability, while the balance sheet shows limited leverage but poor returns on equity. Cash flow issues further exacerbate the company's financial instability, highlighting the need for strategic improvements to achieve financial sustainability.

Income Statement

Sera Prognostics has experienced negative revenue growth and significant losses, as evidenced by negative gross and net profit margins. The TTM data shows a worsening trend in profitability, with net profit margins deeply negative at -303.06%. The company is struggling to generate revenue and control costs, leading to substantial EBIT and EBITDA losses.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.0039, indicating minimal leverage, which is a positive aspect. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio is relatively stable, but the overall financial health is weak due to persistent losses.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash outflows are not supporting earnings. Despite a positive free cash flow to net income ratio, the overall cash flow situation is concerning.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	108.00K	77.00K	306.00K	268.00K	82.00K	25.00K
Gross Profit	-226.00K	-5.00K	96.00K	75.00K	45.00K	14.00K
EBITDA	-31.85M	-32.04M	-35.29M	-42.91M	-33.60M	-17.11M
Net Income	-32.73M	-32.90M	-36.24M	-44.25M	-36.23M	-21.61M
Balance Sheet
Total Assets	111.83M	72.58M	95.44M	116.33M	147.03M	14.80M
Cash, Cash Equivalents and Short-Term Investments	40.16M	46.24M	49.08M	82.70M	105.11M	13.53M
Total Debt	351.00K	840.00K	1.86M	2.31M	128.00K	8.67M
Total Liabilities	23.60M	24.77M	25.28M	17.39M	8.46M	140.37M
Stockholders Equity	88.23M	47.80M	70.16M	98.94M	138.56M	-125.57M
Cash Flow
Free Cash Flow	-26.95M	-14.24M	-27.32M	-35.40M	-32.94M	-17.02M
Operating Cash Flow	-26.28M	-14.19M	-27.19M	-34.61M	-31.64M	-16.87M
Investing Cash Flow	-27.28M	11.74M	438.00K	5.55M	-82.56M	-149.00K
Financing Cash Flow	53.91M	2.61M	752.00K	5.00K	159.59M	9.16M

Sera Prognostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SERA, the sentiment is Positive. The current price of 3.37 is above the 20-day moving average (MA) of 3.18, above the 50-day MA of 3.04, and above the 200-day MA of 3.36, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 57.23 is Neutral, neither overbought nor oversold. The STOCH value of 76.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SERA.

Sera Prognostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRE	55 Neutral	$215.58M	―	-27.01%	―	123.15%	8.21%
ACRS	55 Neutral	$244.83M	-1.65	-101.41%	―	-47.56%	-65.54%
BNR	52 Neutral	$86.58M	―	-22.66%	―	5.33%	75.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SERA	46 Neutral	$127.89M	―	-44.24%	―	0.93%	13.99%
VNRX	43 Neutral	$50.28M	-1.74	―	―	35.10%	39.15%
BDSX	41 Neutral	$52.96M	―	-219.68%	―	25.70%	39.25%

Sera Prognostics Corporate Events

Sera Prognostics Highlights Strategy at Investment Conference

On September 5, 2025, Sera Prognostics presented a new investor presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company highlighted its strategic focus on commercializing the PreTRM® test, supported by a strong financial position with $108.5 million in cash and marketable securities. Sera Prognostics aims to address the significant economic burden of preterm births in the U.S., which account for a substantial portion of neonatal healthcare costs. The company is progressing with Medicaid engagement and anticipates a commercial inflection point as it continues to expand its market presence.

The most recent analyst rating on (SERA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Sera Prognostics stock, see the SERA Stock Forecast page.

Sera Prognostics’ Earnings Call: Strategic Gains Amid Financial Challenges

Sera Prognostics’ recent earnings call painted a picture of a company making strides in strategic initiatives while grappling with financial hurdles. The sentiment was a mix of optimism and caution, as the company showcased progress in data generation, commercial team expansion, and European market preparation. However, these advancements were overshadowed by a decline in net revenue and persistent net losses, indicating current financial challenges despite the potential for future growth.

Sera Prognostics Reports Q2 2025 Financial Results

Sera Prognostics, Inc., a health diagnostics company based in Salt Lake City, Utah, specializes in precision pregnancy care, offering innovative diagnostic tests to predict preterm birth risks and improve maternal and neonatal health outcomes.